Paroxetine

Bibliography

• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990 – 2020: Global Burden of Disease Study. Lancet 1997;349:1498-504
   PubMed Web of Science ®Google Scholar
• Tang SW, Seeman P. Effect of antidepressant drugs on serotonergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 1980;311:255-61
   PubMedGoogle Scholar
• Tang SW, Seeman P, Kwan S. Differential effect of chronic desipramine and amitriptyline treatment on rat brain adrenergic and serotonergic receptors. Psychiatry Res 1981;4:129-38
   PubMedGoogle Scholar
• Wong DT, Perry KW, Bymaster FP. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 2005;4:764-74
   PubMed Web of Science ®Google Scholar
• Owens MJ, Morgan WN, Plott SJ, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305-22
   PubMed Web of Science ®Google Scholar
• Dumbrille-Ross A, Tang SW, Coscina DV. Differential binding of 3H-imipramine and 3H-mianserin in rat cerebral cortex. Life Sci 1981;29:2049-58
   PubMedGoogle Scholar
• Davis A, Morris JM, Tang SW. Temperature-sensitive conformational changes in membrane-bound and solubilized [3H]imipramine binding sites. Eur J Pharmacol 1983;88:407-10
   PubMedGoogle Scholar
• Dumbrille-Ross A, Morris J, Davis A, et al. Temperature-sensitive reversible loss of [3H]imipramine binding sites: evidence suggesting different conformational states. Eur J Pharmacol 1983;91:383-9
   PubMedGoogle Scholar
• Dumbrille-Ross A, Tang SW. Binding of [3H]Ro 11-2465. Possible identification of a subclass of [3H]imipramine binding sites. Mol Pharmacol 1983;23:607-13
   PubMedGoogle Scholar
• Davis A, Morris JM, Tang SW. Solubilization and assay of [3H]imipramine binding sites from human platelets. Eur J Pharmacol 1983;86:353-9
   PubMedGoogle Scholar
• Mellerup ET, Plenge P, Engelstoft M. High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes. Eur J Pharmacol 1983;96:303-9
   PubMedGoogle Scholar
• Tang SW, Helmeste D. Escitalopram. Med Prog 2004;31:497-502
   Google Scholar
• Ramamoorthy S, Bauman AL, Moore KR, et al. Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 1993;90:2542-6
   PubMed Web of Science ®Google Scholar
• Chen F, Larsen MB, Sanchez C, et al. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005;15:193-8
   PubMed Web of Science ®Google Scholar
• Henry LK, Field JR, Adkins EM, et al. Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J Biol Chem 2006;281:2012-23
   PubMedGoogle Scholar
• Neubauer HA, Hansen CG, Wiborg O. Dissection of an allosteric mechanism on the serotonin transporter: a cross-species study. Mol Pharmacol 2006;69:1242-50
   PubMed Web of Science ®Google Scholar
• Plenge P, Gether U, Rasmussen SG. Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites. Eur J Pharmacol 2007;567:1-9
   PubMedGoogle Scholar
• Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989;350:60-75
   PubMedGoogle Scholar
• Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(Suppl 1):1-21
   PubMed Web of Science ®Google Scholar
• Findling RL, Nucci G, Piergies AA, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with Major Depressive Disorder or Obsessive-Compulsive Disorder. Neuropsychopharmacology 2006;31:1274-85
   PubMed Web of Science ®Google Scholar
• Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11-28
   PubMed Web of Science ®Google Scholar
• Liston HL, Devane CL, Boulton DW, et al. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002;22:169-73
   PubMed Web of Science ®Google Scholar
• Albers LJ, Reist C, Helmeste D, et al. Paroxetine shifts imipramine metabolism. Psychiatry Res 1996;59:189-96
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 1995;29(Suppl 1):10-8
   PubMedGoogle Scholar
• Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Center for Drug Evaluation and Research. Available from: http://www.fda.gov/cder.
   Google Scholar
• McKenzie MS, McFarland BH. Trends in antidepressant overdoses. Pharmacoepidemiol Drug Saf 2007;16:513-23
   PubMed Web of Science ®Google Scholar
• Mason J, Freemantle N, Eccles M. Fatal toxicity associated with antidepressant use in primary care. Br J Gen Pract 2000;50:366-70
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 2008;65:94-101
   PubMed Web of Science ®Google Scholar
• FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html
   Google Scholar
• Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80:18-27
   PubMed Web of Science ®Google Scholar
• Bar-Oz B, Einarson T, Einarson A. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007;29:918-26
   PubMed Web of Science ®Google Scholar
• Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-83
   PubMed Web of Science ®Google Scholar
• Kallen B, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301-8
   PubMed Web of Science ®Google Scholar
• Nordeng H, Lindemann R, Perminov KV, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-91
   PubMed Web of Science ®Google Scholar
• Egberts AC, Terborgh J, Brodie-Meijer CC. Serotonin syndrome attributed to tramadol addition to Paroxetine therapy. Int Clin Psychopharmacol 1997;12:181-2
   PubMed Web of Science ®Google Scholar
• John AP, Koloth R. Severe serotonin toxicity and manic switch induced by combined use of tramadol and Paroxetine. Aust NZ J Psychiatry 2007;41:192-3
   PubMed Web of Science ®Google Scholar
• Gonzalez-Pinto A, Imaz H, De Heredia JL, et al. Mania and tramadol-fluoxetine combination. Am J Psychiatry 2001;158:964-5
   PubMed Web of Science ®Google Scholar
• Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coradministration. Ann Pharmacother 1997;31:175-7
   PubMed Web of Science ®Google Scholar
• Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87
   PubMed Web of Science ®Google Scholar
• Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999;19:467-89
   PubMed Web of Science ®Google Scholar
• Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev 2001;7:25-47
   PubMedGoogle Scholar
• Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007;164:201-4
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-59
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007;22:323-9
   PubMed Web of Science ®Google Scholar
• Zhang A, Zhou G, Hoepping A, et al. Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0 (3,7) decanes as a novel class of serotonin transporter inhibitors. J Med Chem 2002;45:1930-41
   PubMedGoogle Scholar
• Ravna AW. Three dimensional models of neurotransmitter transporters and their interactions with cocaine and S-citalopram. World J Biol Psychiatry 2006;7:99-109
   PubMed Web of Science ®Google Scholar
• Ravna AW, Sylte I, Dahl SG. Molecular model of the neural dopamine transporter. J Comput Aided Mol Des 2003;17:367-82
   PubMedGoogle Scholar
• Ravna AW, Sylte I, Dahl SG. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters. J Pharmacol Exp Ther 2003;307:34-41
   PubMedGoogle Scholar
• Chen F, Larsen MB, Neubauer HA, et al. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem 2005;92:21-8
   PubMed Web of Science ®Google Scholar
• Plenge P, Wiborg O. High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions. Neurosci Lett 2005;383:203-8
   PubMedGoogle Scholar
• Larsen MB, Elfving B, Wiborg O. The chicken serotonin transporter discriminates between serotonin-selective reuptake inhibitors. A species-scanning mutagenesis study. J Biol Chem 2004;279:42147-56
   PubMedGoogle Scholar
• Ravna AW, Sylte I, Kristiansen K, et al. Putative drug binding conformations of monoamine transporters. Bioorg Med Chem 2006;14:666-75
   PubMedGoogle Scholar